A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
08/03/2022at 10:48

Small molecules to lead Leo Pharma to greatness

In 2030, Leo Pharma wants to be the world’s leading firm within medical dermatology, and the road there is firmly anchored in small molecules, which is what the company’s scientists do best. Big molecules – which will continue to play a role – will be sourced externally.
Jörg Möller joined Leo Pharma as head of global research and development a year ago, and is now leading an extensive restructuring of the company's R&D division | Photo: MAGNUS MØLLER
by ULRICH QUISTGAARD, translated by daniel pedersen

Leo Pharma has no doubts about where the road ahead is leading it. By the end of the decade, the company aims to be one of the absolute biggest international organizations within medical dermatology, and is currently going through sweeping changes to get there.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Leo Pharma is closing down around 10–15 percent of positions in its R&D unit | Photo: Leo Pharma/PR

    Leo Pharma to terminate up to 150 R&D jobs

    For subscribers

  • Photo: Leo Pharma/PR

    Leo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"

    For subscribers

  • Brian Hilberdink | Photo: Brian Hilberdink

    Leo Pharma poaches Novo Nordisk VP to lead US division

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Tidsvilde Stine/Ritzau Scanpix
Pharma & biotech

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Foto: Saniona / PR
Pharma & biotech

Embattled Y-mabs tightens pipeline focus, reduces staff by 35%

After European and American regulatory authorities have left the biotech company in the cold, Y-mabs downsizes both its pipeline and workforce.

For subscribers

Tobias S. Christensen (right) took up the CEO mantle from his father, Lars Christensen (left) in summer of last year | Foto: Pharmacosmos / Pr
Pharma & biotech

Pharmacosmos to invest in Chinese organization following reimbursement win

The Danish company is the first in China to receive reimbursement approval for a high-dose iron deficiency drug, says Pharmacosmos CEO Tobias Christensen – but the competition is hot on their heels.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Experienced Patent Counsel

  • Application Manager

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Supply Chain Manager

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Lead Data Architect

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Application Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

See all jobs

Jobs

  • Experienced Patent Counsel

  • Application Manager

  • Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Supply Chain Manager

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Lead Data Architect

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Application Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge